stockrow
Saturday 7 November 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024.
- Revenue
- −58.9%
- EPS
- +95.6%
- Free cash flow
- +13.8%
- Total debt
- −83.9%
Quarter to June 2026, against a year earlier
0.40
0.01
−2.44%
Follow JAGX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.06 | 0.16 | 0.36 | 0.22 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.33) | 0.55 | (0.76) | (0.55) | |
P/B ratio |
0.36 | 0.00 | 0.00 | 1.37 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(0.05) | 0.25 | 1.13 | 0.70 | |
EV/EBITDA |
0.06 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.22 | (0.99) | (0.55) | (0.32) | |
EV/FCF |
0.20 | (0.91) | (0.53) | (0.31) | |
Quick Ratio |
0.27 | 0.25 | 0.23 | 0.14 | |
Current Ratio |
0.69 | 0.50 | 0.50 | 0.81 | |
Net Debt/EBITDA |
0.73 | 0.09 | (0.35) | (0.62) | |
Debt/Assets |
5.05% | 29.59% | 39.36% | 15.46% | |
Debt/Equity |
0.35 | (0.70) | (0.81) | 1.75 | |
Asset Turnover |
0.67 | 0.67 | 0.25 | 0.22 | |
Operating CF/Net income |
0.42 | (1.26) | 0.24 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | (0.10) | |
Interest Coverage |
(47.19) | 14.57 | (160.92) | (1,206.33) | |
Research and Development Expense of Revenue |
272.33% | 19.38% | 442.44% | 118.65% | |
Selling, General and Administrative Expense of Revenue |
363.67% | 24.68% | 221.45% | 198.86% | |
Intangible Assets out of Total Assets |
0.44 | 0.42 | 0.42 | 0.35 | |
Share Based Compensation of Revenue |
13.96% | 0.76% | 3.59% | 4.38% | |
Graham Net Nets |
(6.68) | (6.81) | (8.82) | (6.12) | |
Graham Number |
0.00 | 10,571.46 | 28,029.58 | 0.00 | |
Earnings Yield |
(17,523.73%) | (7,709.87%) | (5,485.56%) | (2,944.78%) | |
Free Cash Flow Yield |
(419.41%) | (170.03%) | (586.01%) | (1,039.41%) | |
Revenue per Share |
22.69 | 589.30 | 275.04 | 1,063.10 | |
Operating CF per Share |
(98.85) | 256.69 | (466.59) | (1,616.90) | |
Capex per Share |
0.00 | 0.00 | (3.49) | (18.62) | |
Free Cash Flow per Share |
(98.85) | 256.69 | (470.08) | (1,635.52) | |
Cash per Share |
122.04 | 292.56 | 665.88 | 1,216.21 | |
Shareholders Equity per Share |
91.13 | (457.91) | (1,588.86) | 1,503.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
91.13 | (457.91) | (1,588.86) | 1,503.10 | |
Free Cash Flow |
(5.34) | 8.83 | (5.53) | (4.74) | |
Working Capital |
(7.85) | (20.48) | (20.31) | (6.72) | |
Capital Expenditures |
— | — | (0.04) | (0.05) | |
Net Current Asset Value |
(11.74) | (32.98) | (36.67) | (15.71) | |
EV/EBIT |
0.06 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.76 | 0.83 | 1.67 | 1.41 | |
Average Payables |
5.71 | 5.99 | 6.99 | 6.50 | |
Average Inventory |
9.02 | 9.19 | 9.47 | 10.15 | |
Average Assets |
41.23 | 44.45 | 45.87 | 53.97 | |
Average Common Equity |
4.66 | (7.46) | (7.34) | 7.49 |
Columns are period end dates · fundamentals updated 26 Oct 2026